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Abstract Primary steroid-resistant nephrotic syndrome
(SRNS) is characterized by childhood onset of proteinuria
and progression to end-stage renal disease. In 26% of
cases it is caused by recessive mutations in NPHS2 (po-
docin). Congenital nephrotic syndrome (CNS) is caused
by mutations in NPHS1 (nephrin) or NPHS2. In three
families mutations in NPHS1 and NPHS2 had been re-
ported to occur together, and these tri-allelic mutations
were implicated in genotype/phenotype correlations. To
further test the hypothesis of tri-allelism, we examined a
group of 62 unrelated patients for NPHS1 mutations, who
were previously shown to have NPHS2 mutations; 15 of
62 patients had CNS. In addition, 12 CNS patients with-
out NPHS2 mutation were examined for NPHS1 muta-
tions. Mutational analysis yielded three different groups.
(1) In 48 patients with two recessive NPHS2 mutations
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(11 with CNS), no NPHS1 mutation was detected, except
for 1 patient, who had one NPHS1 mutation only. This
patient was indistinguishable clinically and did not have
CNS. (2) In 14 patients with one NPHS2 mutation only (4
with CNS), we detected two additional recessive NPHS1
mutations in the 4 patients with CNS. They all carried the
R229Q variant of NPHS2. The CNS phenotype may be
sufficiently explained by the presence of two NPHS1
mutations. (3) In 12 patients without NPHS2 mutation (all
with CNS), we detected two recessive NPHS1 mutations
in 11 patients, explaining their CNS phenotype. We report
ten novel mutations in the nephrin gene. Our data do not
suggest any genotype/phenotype correlation in the 5 pa-
tients with mutations in both the NPHS1 and the NPHS2
genes.
Keywords Steroid-resistant nephrotic syndrome ·
Congenital nephrotic syndrome · NPHS1 · NPHS2 ·
Mutational analysis
Introduction
Nephrin and podocin, the protein products of the NPHS1
and NPHS2 genes, directly interact via their C-terminal
domains in a protein-protein interaction pathway that is
responsible for maintaining glomerular podocyte foot
process integrity and function [1, 2]. The presence of two
recessive mutations in the NPHS1 and NPHS2 genes that
impair function of these proteins results in altered podo-
cyte structure and function. The glomerular filtration bar-
rier to protein is then defective [3]. The mechanistic con-
sequence (phenotype) is that protein leaks from blood into
the urinary space to be lost from the body in the urine,
thereby causing the nephrotic syndrome (NS). There has
been increasing realization that heterozygous mutations
in more than one gene coding for proteins involved in
important protein-protein interaction pathways may to-
gether impact the phenotype, and therefore affect clinical
disease, including age of onset, severity, and outcome [4].
These associated heterozygous mutations might con-
tribute to a genetic modifier effect well recognized to be
important in determining the ultimate phenotype. This
additional level of genetic complexity is superimposed on
already complex factors such as the functional conse-
quence of a mutation.
The range of phenotypes in childhood NS has tradi-
tionally been described in relation to age at onset. Ad-
ditional pathological features derived from renal biopsy
are superimposed on this clinical classification. Steroid-
resistant nephrotic syndrome (SRNS) has been described
as childhood onset of proteinuria, rapid progression to
end-stage renal disease (ESRD), resistance to standard
steroid therapy, and absence of recurrence after renal
transplantation [5]. In SRNS about 75% of patients ex-
hibit renal histology of focal segmental glomeruloscle-
rosis (FSGS) and 20% show minimal change nephrotic
syndrome (MCNS). Following the identification of the
NPHS2 gene encoding podocin (OMIM 604766) [6],
different groups have demonstrated that mutations in the
NPHS2 gene represent a frequent rather than a rare cause
of SRNS, since they occur in approximately 26% of
unrelated patients with SRNS [7, 8]. It has been pro-
posed, based on a very small number of patients [6], that
SRNS patients with two recessive mutations in NPHS2
do not respond to standard steroid treatment. We recently
confirmed this hypothesis in 190 patients with SRNS and
124 patients with steroid-sensitive nephrotic syndrome
(SSNS). We showed that SRNS patients with two re-
cessive mutations in NPHS2 have a reduced risk for re-
currence of FSGS in a renal transplant compared with
children without mutations (8% compared with 35%) [8].
Congenital nephrotic syndrome (CNS) is a clinical
syndrome where proteinuria and edema are present before
birth and are associated with a large placenta, prematu-
rity, and marked edema at birth [9]. Histology shows a
wide variability but fibrotic lesions, focal mesangial cell
hyperplasia, tubular atrophy, and dilatation of glomerular
capillaries are common features [10, 11]. The most fre-
quent cause of CNS is CNS of the Finnish type (CNF),
which is an autosomal recessive disorder with a higher
incidence in Finland (1:10,000 births) [12] than in other
countries [13]. Recessive mutations in NPHS1, encoding
nephrin (OMIM 602716) [14], are the most frequent cause
of CNS (CNF). Of Finnish CNS patients, 94% show one
of two mutations: a two-base pair deletion in exon 2 (Fin
major) or a nonsense mutation in exon 26 (Fin minor)
[14]. An R1160X nonsense mutation was recently found
to be a founder mutation in the Maltese population [15].
In other populations no mutation “hot-spots” have been
found, and mutations are equally distributed over the
NPHS1 gene [16, 17].
The gene products of the two recessive genes, causing
SRNS and CNS, nephrin (encoded by NPHS1) and po-
docin (encoded by NPHS2), were identified as being
important for the function of the glomerular slit mem-
brane of podocyte foot processes, which constitutes the
primary molecular sieve of the glomerulus [18]. Data
showing evidence of a functional inter-relationship be-
tween nephrin and podocin within the podocyte were
reported recently [15] by identifying mutations both in
NPHS1 and NPHS2 in three families. A di-genic inher-
itance resulting in a tri-allelic number of mutations was
thought to modify the histological phenotype from CNS
of the Finnish type (CNF) to congenital FSGS [15].
We therefore examined a cohort of 74 patients with
childhood NS for the NPHS1 and NPHS2 genes to test for
the frequency of mutations in more than one of the two
genes and relate the findings to the phenotype, if possible.
We performed mutational analysis in the promoter
region and all 29 NPHS1 exons in 48 patients (11/48
presented as CNS) in whom we had detected two reces-
sive NPHS2 mutations and in 14 patients (4/14 presented
as CNS) in whom we had detected one heterozygous
NPHS2 mutation only. We also examined 12 CNS pa-
tients without NPHS2 mutation for NPHS1. Our primary
goal was to determine (1) whether there was any evidence
of NPHS1 mutations in the 63 patients with NPHS2 mu-
1341
tations, (2) whether there were any genotype/phenotype
correlations of combined NPHS1 and NPHS2 mutations,
(3) whether mutations in NPHS1 could fully explain the
phenotype seen in patients with CNS and no NPHS2
mutation.
In conclusion, we report ten novel NPHS1 mutations.
We found 5 patients with combined mutations in NPHS1




Blood samples for mutational analysis, clinical data, and informed
consent were obtained from patients or their parents (http://
www.renalgenes.org). Genomic DNA was isolated directly from
blood samples by standard methods [19] using the QIAamp blood
kit (Qiagen, Valencia, Calif., USA). Ethic committee approval was
obtained from the ethic commission of the University of Freiburg,
Germany and was sought from the University of Michigan, Ann
Arbor. The clinical diagnoses of SRNS and/or CNS were estab-
lished by pediatric nephrologists from different centers of pediatric
nephrology according to published criteria [20, 21]. Of the 62 pa-
tients with NPHS2 mutations, 46 had received standard steroid
treatment and proved resistant, only 5 did not receive steroids. Of
these 5 patients, 3 had congenital onset, for the other 2 the reason
for not receiving steroids is unknown. For 11 patients no data on the
treatment modalities were available, but no patient was reported to
be steroid sensitive. Of the 12 CNS patients without NPHS2 mu-
tations, 3 had received standard steroid treatment and proved re-
sistant, in 8 patients no standard steroid treatment was performed,
and for 1 patient no data on the treatment modalities were available.
Three groups of patients were screened for NPHS1 mutations: pa-
tients with two recessive NPHS2 mutations, patients with one
heterozygous NPHS2 mutation only, and CNS patients with no
NPHS2 mutation. In the third group, 2 patients (F475 II-1 and
F1328 II-1) also had one affected sibling. Since these siblings
showed a similar phenotype we have not included them in the
number calculations for clinical data. Patients of groups I, II, and III
with mutations in the NPHS1 gene were divided into subgroup A
(group I patients), subgroup B (group II patients), and subgroup C
(group III patients) in Table 1. For clinical evaluation we used a
standard questionnaire (http://www.renalgenes.org) as previously
described [7]. Characteristic features defining the clinical diagnosis
were: age of onset, initial symptoms, histology of the kidney bi-
opsy, progression to ESRD, and renal transplantation (Table 1).
None of the patients showed significant extrarenal manifestations
of other organ systems. CNS was defined as the presentation of NS
within the first 2 months of life, because one-quarter of the CNF
children presented with edema or abdominal distention at birth,
another quarter presented during the 1st week of life, and all un-
treated patients developed full-blown NS before the age of
3 months [21]. CNF in kidney biopsy usually presents as proximal
tubular dilatation and diffuse glomerular mesangial hypercellularity
at an early stage. Later biopsies show mesangial hypercellularity
and degenerative changes such as fibrotic thickening of the Bow-
man’s capsule and interstitial fibrosis [15, 21, 22]. In the patients
with two recessive NPHS1 mutations (Table 1, subgroup B and
subgroup C), consanguinity was known for 8 of 15 (53%). The
ethnic background of the patients was central European, Turkish,
and Arabic.
Mutational analysis
Mutational analysis for NPHS1 was performed by direct se-
quencing of the promoter region and of all 29 exons of the NPHS1
gene for one strand. For all 18 amplicons (compromising the
promoter region and all 29 exons), the forward primers were used
for sequencing as described previously [23, 24]. All mutations
were confirmed by sequencing the complementary strand. Known
single nucleotide polymorphisms within the primer sequences
were avoided (http://genome.ucsc.edu/), because single nucleotide
variants within the primer sequence can suppress amplification of
one of the two alleles of the amplified product. To rule out poly-
morphisms, at least 160 chromosomes of 80 healthy control indi-
viduals (age and ethnic background similar to the patients screened
for mutations in NPHS1) were checked for novel mutations by
restriction enzyme digestion and denaturing high-performance
liquid chromatography. For sequence evaluation the program
SEQUENCHER version 4.1.4 (GeneCode, Ann Arbor, Mich.,
USA) was used. All patients had undergone previous mutational
analysis of podocin [8] and exons 6, 7, 8, and 9 of the WT1 gene
(data not shown, Ruf et al., in press). None of the patients in this
study showed mutations in exons 6, 7, 8, and 9 of the WT1 gene.
Results
Clinical data and summary of results
The study included 75 unrelated patients with NS. Clin-
ical data are shown in Tables 1 and 2. Renal biopsy results
in patient group I were FSGS 28 of 48 (58%), MCNS 9 of
48 (19%), mesangioproliferative glomerulonephritis 2 of
48 (4%), IgM nephropathy 1 of 48 (2%), Alport neph-
ropathy 1 of 48 (2%), CNF 1 of 48 (2%), and no data or
no biopsy performed 6 of 48 (13%) (Table 2). Renal bi-
opsy results in patient group II were FSGS 5 of 14 (36%),
MCNS 5 of 14 (36%), diffuse mesangial sclerosis (DMS)
1 of 14 (7%), and no data or no biopsy performed 3 of 14
(21%) (Table 2). Renal biopsy results in patient group III
were FSGS 2 of 12 (17%), MCNS 2 of 12 (17%), DMS 1
of 12 (8%), CNF 2 of 12 (17%), and no data or no biopsy
performed 5 of 12 (41%) (Table 2). The median age at
onset was 2.4 years in patient group I (median 3.3 years
after subtracting the 11 CNS patients), 1.3 years in patient
group II (median 4.0 years after subtracting the 4 CNS
patients), and 0.0 years in patient group III. CNS was
diagnosed in 11 of 48 (23%) patients of group I and 4 of
14 (29%) patients of group II; 23 of 48 (48%) patients of
group I progressed to ESRD with a median age of
9.3 years; 3 of 14 (21%) patients of group II progressed to
ESRD with a median age of 13.0 years; 5 of 12 (42%)
patients of group III progressed to ESRD with a median
age of 3.4 years (Table 2). There were 48 patients with
two recessive NPHS2 mutations (Table 2, group I), but
only 1 of them showed an additional heterozygous
NPHS1 mutation (Table 1, subgroup A). There were 14
patients with one heterozygous NPHS2 mutation only
(Table 2, group II); 4 of these patients had two additional
recessive NPHS1 mutations (Table 1, subgroup B).
Twelve CNS patients showed no NPHS2 mutation (Ta-
ble 2, group III), but 11 of them had two recessive NPHS1







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Detection of 10 novel and 9 known NPHS1 mutations
Since the result of the NPHS2 mutational analysis has
been reported previously [8], we describe here only the
results for the NPHS1 mutational analysis. NPHS1 mu-
tational analysis showed 19 different mutations in the
NPHS1 gene; 10 were missense mutations, 3 were non-
sense mutations, leading to a stop codon, 4 were frame-
shift mutations, leading to a premature stop codon, and 2
were splice site mutations (Table 1). Ten of the mutations
have never been described before and are therefore novel.
All novel mutations were absent from 160 chromosomes
of healthy control individuals.
The novel mutations include (Table 1): (1) a C65T
transition leading to a conservative amino acid exchange
A22 V (codon conserved in mice) was found homozy-
gously in A140; (2) a C385T transition leading to a
conservative amino acid exchange L130F (codon con-
served in mice) was found heterozygously in F1328 II-1
and F1328 II-3; (3) a C1135T transition leading to a non-
conservative amino acid exchange R379 W (codon con-
served in mice and Drosophila melanogaster) was found
homozygously in F212; (4) a T1258G transversion lead-
ing to a conservative amino acid exchange F420 V (codon
conserved in mice) was found heterozygously in F1017;
(5) a T1738G transversion leading to a non-conservative
amino acid exchange W580G (codon conserved in mice
and Drosophila melanogaster) was found heterozygously
in F228; (6) a G2014C transversion leading to a conser-
vative amino acid exchange A672P (codon conserved in
mice and Drosophila melanogaster) was found homozy-
gously in F1093; (7) a G2971C transversion leading to
a conservative amino acid exchange V991L (codon not
conserved in evolution) was found heterozygously in
F1268; (8) a C2479T transition leading to a premature
stop codon (R827X) was found heterozygously in F228;
(9) a deletion of C at position 1814 in the 605th codon
inducing a frameshift resulting in a stop codon at V621X
was found homozygously in F439; (10) an obligatory
splice site mutation IVS20+2T!A involving the 50 donor
splice site of intron 20 was found homozygously in F294.
In 4 patients of three families (F475 II-1, F475 II-2,
F435, and F1296) we found homozygously a C2552T
transition leading to a conservative amino acid exchange
A851 V (codon conserved in mice and Drosophila mel-
anogaster). This mutation was not found in any other
patient and was absent from 94 healthy control individ-
uals. It only occurred in combination with the homozy-
gous mutation: deletion TCA, insertion CC at position
2617, leading to a stop codon at position 904 (Table 1).
Both mutations are localized in exon 19, only 65 base
pairs apart from each other. In the healthy mother (F475 I-
2) both mutations were found heterozygously. Both mu-
tations were first described by Beltcheva et al. [16], but
this publication does not specify if they occur in the same
patient. Both mutations were not found in any other pa-
tients. The combined appearance of A851V and delT-
CAinsC2617 is apparently due to linkage disequilibrium.
In patient F1017, originally from Germany, we describe
the first occurrence of Fin major [delCT121 (A90X)]
outside Scandinavia.
Two recessive NPHS2 mutations in combination
with single heterozygous NPHS1 mutation
In 1 patient with SRNS and two homozygous NPHS2
mutations (F1268), one heterozygous NPHS1 mutation
was found (Table 1, subgroup A). Since the amino acid
exchange V991L is conservative and is not conserved in
evolution, and since the patient (F1268) is originally from
Oman, this mutation might represent a rare innocuous
polymorphism not found in the 80 Caucasian healthy
control individuals.
Single heterozygous NPHS2 mutation
in combination with two recessive NPHS1 mutations
In 4 of 14 patients with one heterozygous NPHS2 muta-
tion only, two recessive NPHS1 mutations were found
(Table 1, subgroup B). All of these 4 patients had CNS
and showed only one heterozygous NPHS2 mutation with
the amino acid exchange R229Q. No mutation in NPHS1
was found in 10 of 14 patients of this group.
Two recessive NPHS1 mutations in CNS patients
with no NPHS2 mutation
In 11 of 12 CNS patients with no NPHS2 mutation, we
detected two recessive NPHS1 mutations (Table 1, sub-
group C). These mutations would explain their CNS
phenotype.
Single heterozygous mutations detected in NPHS2
The single heterozygous NPHS2 mutations found in 14
patients (Table 2, group II) were described by Ruf et al.
[8], but because of the importance of combined NPHS1
and NPHS2 mutations, they should be reassessed. In 8 of
14 patients we found the common amino acid exchange
R229Q. In 2 of 14 patients we found V290M heterozy-
gously, in 1 of 14 patients we observed R138Q heterozy-
gously and in 1 of 14 patients E310V heterozygously. All 4
occur in compound heterozygous or homozygous muta-
tions in other patients [8] and for R229Q and R138Q clear
functional relevance has been demonstrated [25, 26]. There
was 1 of 14 patients with the amino acid exchange A242V
and 1 of 14 patients Q328R. The significance of these
single heterozygous mutations remains unclear.
Discussion
We report ten novel NPHS1 mutations in children with
CNS. Only 5 patients with combined mutations in NPHS1
1345
and NPHS2 were identified. We did not observe any
obvious genotype/phenotype correlations regarding age at
onset and histological presentation.
Koziell et al. [15] first reported mutations both in
NPHS1 and NPHS2 in four individuals from three dif-
ferent families with congenital FSGS. One patient showed
a homozygous NPHS1 mutation and only one heterozy-
gous NPHS2 mutation (R229Q). Three patients (from two
families) showed only one heterozygous NPHS1 mutation
and a homozygous NPHS2 mutation. Caridi et al. [27]
reported one patient with only one heterozygous NPHS1
mutation and only one heterozygous NPHS2 mutation
(R229Q). To further evaluate these hypotheses of a di-
genic effect for mutations in NPHS1 and NPHS2, we
performed mutational analysis of NPHS1 in a cohort of 74
patients in whom we had previously performed analysis
of NPHS2 [8]. We describe here 5 patients with a “tri-
allelic hit”, 4 patients (F435, F451, F1296, A140) with
two recessive NPHS1 mutations and only one heterozy-
gous NPHS2 mutation (Table 1, subgroup B), and one
patient (F1268) with only one heterozygous NPHS1 mu-
tation and two homozygous NPHS2 mutations (Table 1,
subgroup A). In all 4 patients of subgroup B, the single
heterozygous mutation in the NPHS2 gene was R229Q.
This mutation has previously been described as a poly-
morphism, since it was found in 3% of all chromosomes
in 100 healthy controls [7]. A functional relevance had
been claimed for R229Q. The codon is highly conserved
in evolution, the amino acid exchange is non-conserva-
tive, and it segregated with the disease in certain families.
The encoded peptide is altered and the interaction with
nephrin in nephrin-binding assays diminished [25]. How-
ever, our group and others recently detected R229Q in
patients with SRNS, SSNS, and in healthy controls [8,
27]. In this study, in the 4 patients bearing this sequence
variant as the third altered allele, the two recessive
NPHS1 mutations were sufficient to explain their CNS
phenotype. As far as clinical data were available, no
significant clinical pleiotropic difference was noticed
between these 4 patients and CNS patients with two re-
cessive NPHS1 mutations and absence of NPHS2 muta-
tion (Table 1, subgroup B and C, respectively).
In F1268 we found only one heterozygous NPHS1
mutation and two homozygous NPHS2 mutations (Ta-
ble 1, subgroup A). The two homozygous NPHS2 muta-
tions found in this patient have both been previously
described [7, 8]: an insertion of T at position 460–467
inducing a frameshift resulting in a stop codon at V165X
and a G709C tranversion leading to a conservative amino
acid exchange E237Q (Table 1, subgroup A). To date the
second sequence variant has only been found heterozy-
gously by our group in 1 SRNS and 1 SSNS patient [8].
Recently, we detected this sequence variant heterozy-
gously paired in cis with a heterozygous splice site mu-
tation and in trans with a heterozygous deletion in a
SRNS patient (Mucha et al., unpublished data). These
findings support the suspicion that E237Q might be a rare
polymorphism, even though it was absent from 80 healthy
controls.
The NPHS1 mutation G2971C that leads to a conser-
vative amino acid exchange V991L was found heterozy-
gously in F1268. This amino acid exchange is conserva-
tive and the codon is not conserved in evolution. We
could not find this mutation in 196 chromosomes of 98
healthy control individuals. However, since this family is
from the Arab country of Oman, it might still represent a
rare polymorphism in the Arab population, not detected
in healthy controls from central Europe. Since both the
NPHS2 variant E237Q and the NPHS1 variant V991L
probably represented innocuous polymorphisms, the pa-
tient’s phenotype most likely is due to the homozygous
NPHS2 mutation V165X (Table 1, subgroup A). This is
consistent with the finding that the clinical data available
for this patient are similar to clinical data from patients
with two recessive NPHS2 mutations and no NPHS1
mutation (Table 1, subgroup A; [8]): Age at onset was
1.6 years compared with 2.4 years; initial symptoms were
acute edema and fever. Steroid therapy was started re-
cently. No biopsy has been performed to date.
Caridi et al. [27] reported one patient with one het-
erozygous NPHS1 mutation only (amino acid exchange
A907T) and R229Q in NPHS2. This patient has an age at
onset of proteinuria of 1.4 years, is steroid sensitive, and
has FSGS histology. However, the patient’s healthy moth-
er showed the same molecular findings.
Koziell et al. [15] reported co-existence of NPHS1 and
NPHS2 mutations in four patients from three families.
The third mutation was suspected to modify the histo-
logical phenotype from CNS of the Finnish type (CNF) to
congenital FSGS, which was observed in all 4 patients.
We report 5 patients with combined NPHS1 and NPHS2
mutations. Biopsy showed MCNS in 1 of 5 patients, DMS
in 1 of 5 patients, and was not performed in 3 of 5 patients
(Table 1, subgroup A and subgroup B). Congenital FSGS
was not reported in any of our patients, so we cannot
compare these findings.
We further examined another 12 CNS patients with-
out NPHS2 mutation. In 11 of 12 patients two recessive
NPHS1 mutations were found (Table 1, subgroup C), ex-
plaining their CNS phenotype. Two patients (F475 and
F1328) also had affected siblings and shared the genotype
with them. The clinical expression of the disease in these
siblings was indistinguishable (Table 1, subgroup C).
In family F1328 we report 2 affected individuals with
compound heterozygous NPHS1 mutations and an un-
usually mild phenotype for the disease, characterized by
absence of ESRD even at 24.0 and 20.0 years of age
(Table 1, subgroup C). The mutations are a heterozygous
C385T transition leading to the conservative amino acid
exchange L130F, and a heterozygous G1868T transver-
sion leading to the non-conservative amino acid exchange
C623F. None of our other patients showed these muta-
tions. L130F is novel; a heterozygous C623F mutation
was described previously [23]. Other cases with a mild
phenotype have been described with NPHS1 mutations.
Remission of proteinuria in cases with characteristic CNF
histology has been reported [28]. Koziell et al. [15] de-
scribed a mild phenotype in Maltese patients with ho-
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mozygous R1160X, a founder mutation in the Maltese
population. Patrakka et al. [22] reported clinical features
resulting from different NPHS1 mutations. They describe
a milder phenotype in one patient with Fin major and a
missense mutation compared with patients with Fin major
and/or Fin minor mutations only [22]. F1328 II-1 is a 24-
year-old patient with NS from birth. He is steroid resistant
and his renal biopsy (obtained at the age of 7.8 years)
showed mild FSGS. To date his renal function is normal
and he does not need treatment. His sister F1328 II-3, who
shares the same genotype, also exhibits a very similar
phenotype (NS, normal renal function, no treatment). Her
renal histology, however, differs and was without patho-
logical findings at the age of 19.5 years (by light mi-
croscopy, immunohistochemistry, and electron micros-
copy). These findings emphasize that there can be rare
cases of unusually mild phenotypes in patients with
NPHS1 mutations.
In the group of SRNS patients with two recessive
NPHS 2 mutations (Table 2, group I), 11 of 48 (23%)
patients showed CNS. This confirms the finding that
CNS, which usually results from recessive mutations in
NPHS1, can also result from NPHS2 mutations [8, 15],
and supports the genetic heterogeneity of CNS. The per-
centage of CNS patients with NPHS2 mutations is still
surprisingly high. Within the group of 27 patients with
CNS (Table 2 11 patients of group I, 4 patients of group
II, and 12 patients of group III), we found in 15 (55%)
patients two recessive NPHS1 mutations, and in 11 of 27
(41%) patients two recessive NPHS2 mutations. No mu-
tation was found in 1 of 27 (4%) patients with CNS.
When comparing phenotypes between these two CNS
groups (patients with two recessive NPHS1 mutations
versus patients with two recessive NPHS2 mutations), we
notice especially differences in the biopsy results. Of the
CNS patients with two recessive NPHS2 mutations, 7 of
14 (50%) showed FSGS (2/14 MCNS, 1/14 CNF, 1/14
MP, 3/14 not performed) [8]. This confirms the previous
findings, since NPHS2 has been described as causative for
SRNS with FSGS [6]. Karle et al. [7] found FSGS in 75%
of NPHS2 patients. Biopsy findings in the 15 CNS pa-
tients with two recessive NPHS1 mutations (Table 1,
subgroup B and subgroup C) were surprisingly diverse:
only 2 of 15 results showed the histological picture of
CNF [in 1 case the biopsy report could not exclude CNF
(F435)]. In 3 of 15 patients the biopsy revealed MCNS,
which is unusual for NPHS1 patients. One patient showed
mild FSGS, but the biopsy was performed at the age of
7.8 years. DMS was found in 2 of 15 patients. In 5 of 15
patients no biopsy was performed, and in 2 of 15 results
were not available. In CNS patients with two recessive
NPHS2 mutations, 6 of 14 (43%) developed ESRD at a
median age of 6.0 years and all 6 (43%) had kidney
transplants at a median age of 7.2 years [8]. In CNS pa-
tients with two recessive NPHS1 mutations, 5 of 15 (33%)
developed ESRD at a median age of 3.0 years and all 5
(33%) had kidney transplants at a median age of 4.0 years
(Table 1, subgroup B and subgroup C).
In addition to the 19 NPHS1 mutations in Table 1,
we identified in 8 patients the known sequence variant
G1223A (R408Q) heterozygously. Lenkkeri et al. [23]
considered R408Q a mutation, even though it was found
heterozygously in 4 of 30 healthy control individuals, and
in a Finnish patient, in addition to 2 other heterozygous
mutations. We detected this sequence variant heterozy-
gously in 5 of 49 (10%) patients of group I, 1 of 14 (7%)
patients of group II, 2 of 14 (14%) patients of group III
(F228, F1017) and 10 of 83 (12%) healthy controls, and
therefore consider it an innocuous polymorphism.
In conclusion, in this study we did not find any evi-
dence for di-genic inheritance of NPHS1 and NPHS2
mutations as a “tri-allelic hit” that would result in phe-
notypic modifications. Compared with previously pub-
lished data based on a limited number of patients, the
frequency of patients carrying combined mutations in
NPHS1 and NPHS2 is rather low. We report 4 patients
with two recessive NPHS1 mutations in addition to the
heterozygous NPHS2 sequence variant R229Q. The phe-
notype of our 4 patients (Table 1, subgroup B) was not
altered by the presence of R229Q. A striking difference in
the phenotype of these patients compared with the phe-
notype of patients with two recessive NPHS1 mutations
without NPHS2 mutation could not be observed.
In 1 patient only one heterozygous NPHS1 mutation
and two recessive NPHS2 mutations were found (Table 1,
subgroup A), as reported by Koziell et al. [15] for 3 pa-
tients from two families. The phenotype in our patient
does not differ from other patients with two recessive
NPHS2 mutations and without mutation in NPHS1.
A patient with only one heterozygous NPHS1 mutation
and only one heterozygous NPHS2 mutation, as described
earlier [27], has not been identified in our study. In the
limited number of 5 patients, our data does not suggest
that patients with combined mutations in NPHS1 and
NPHS2 show any genotype/phenotype correlation.
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